Evidence Hub

Quantum mechanics-based multi-tensor AI/ML as predictor of patients' overall survival, gene targets, and drug responses from their glioblastoma tumors' whole genomes

O. Alter, S. Ponnapalli, Marissa Coppola, Angela C. Gushue, Tessa O. House, Penelope Miron, Kristy L. S. Miskimen, K. Waite et al.

Journal of Clinical Oncology, 2026

251 participants

Abstract

3020

Background:

The drug failure rate has increased to ~95%, despite the growth in targeted therapies. As clinical trials demonstrated, a targeted gene alone does not predict whether patients have longer life expectancy in response to the drug. As studies with model organisms showed, the effect of the drug, and the mechanisms underlying it, depend on the entire multi-ome. But multi-omic data are small-cohort, noisy, and high-dimensional, i.e., extremely difficult to model.

Methods:

We have developed our artificial intelligence and machine learning (AI/ML) to overcome these challenges [doi: 10.1073/pnas.0530258100, 10.1158/1538-7445.AM2025-CT227]. We demonstrated our algorithms in the unsupervised modeling of, e.g., whole genomes of 85 astrocytoma patients. Mechanistic interpretation showed that the modeling blindly removed batch effects, separated normal demographic variations, and discovered a disease-specific genome-wide pattern of DNA copy-number alterations. This pattern was used to derive an actionable predictor of patients’ overall survival (OS) and gene targets to sensitize their tumors. We computationally validated both the predictor and the modeling in federated studies of mutually-exclusive sets of 59–251 patients. The modeling repeatedly discovered a representation of the predictor in every study, across astrocytoma grades II, III, and IV, i.e., glioblastoma (GBM), patients. We experimentally validated the predictor in a clinical trial of 79 GBM patients,…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 251 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free